Hypermarcas profit rises 151%

The net profits of the largest Brazilian company Hypermarcas, personal care, increased by 151.4% in the fourth quarter of 2012, compared to the previous year, to $ 124,7 million. The company's consolidated net revenues increased 22% in the period and reached r $ 1.02 billion.
The consumer products division of Hypermarcas, bringing together brands like Bozzano, Risqué and Monange, began to recover in the last three months of 2012, with a high of 14.5% in net revenue, after advancing only 2% and 1% in the third and second quarters of the year, respectively. A series of operational and commercial changes implemented by the company last year contributed to the turnaround.
The business side, the sales force was unified and expanded in October, increasing staff productivity and the frequency of visits to points of sales. The breakthrough in manufacturing and Logistics Division consolidation in a factory in Senador Canedo (GO) and a distribution center in Goiânia, also began to bring a result. The entire operation of consumption will be centered at these locations until the end of the semester.
The company expects to complete by the end of the year the 43% reduction in the number of consumer product brands in order to focus on the most important and profitable assets.
The unit, whose portfolio includes Benegripe, Estomazil and Coristina D, continued pulling the result up with 31% increase in net revenues in the period. However, the Division's growth was below the expectations of analysts of Itaú BBA, Bradesco and Goldman Sachs, who predicted a high of 38% on average. The increase in consumer income, on the other hand, surprised positively analysis teams, which projected a high around 8%.
"With more consistent support to the brand portfolio of non-prescription drugs (OTC) in the media, greater efficiency in medical detailing and expansion of the portfolio of generics, the demand for the company's retail pharmaceutical products peaked in 2012," said Hypermarcas in report. According to the company, the performance of the Division "farma" was also boosted by a weaker basis of comparison in the fourth quarter of 2011.
Collaborated to the significant increase of profit costs less and better operating performance. Analysts had expected a more modest, because they had a load of taxes so low during the period. Taxes accounted for only 2.5% of earnings before interest, taxes, depreciation and amortization (Ebitda) of the company in the range, while analysts projected a percentage of up to 40%. The company's adjusted Ebitda increased by 71% in the fourth quarter, to $ 230,2 million.
Net debt decreased by $ 43.4 million in 2012, reaching $ 2.7 billion at the end of the year. The company had net income of r $ 203,9 million in the year, reversing a loss of r $ 54.6 million in 2011. Annual net revenue grew by 16.5% and reached r $ 3.87 billion.
The shares rose 2.84 percent Hypermarcas yesterday, to $ 18th. From the beginning of 2012 up to now, the roles had appreciation of 113%.